Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CodaVax-RSV First-in-Human Safety and Immunogenicity Study
NCT04295070Phase 1Completed
- Sponsor
- Codagenix
- Start
- Jul 2020
- Primary completion
- Mar 2021
- Modality
- Live Attenuated Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of codavax-rsv in respiratory syncytial virus infection (RSV) (3 arms), sponsored by Codagenix. Primary endpoints: Reactogenicity counts and percentages, Adverse events counts and percentages and 1 more. Started Jul 2020; status: completed.
02
Drugs
codavax-rsv
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT04295070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04295070.